吉利德科学将收购Ouro Medicines,推进其首创的T细胞衔接器项目以治疗自身免疫性疾病

美股速递
Yesterday

吉利德科学已达成协议,将收购Ouro Medicines公司,此举旨在加速推进其首创的T细胞衔接器项目,该项目的重点在于开发针对自身免疫性疾病的创新疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10